Sie sind hier: Startseite Termine Market Access of Orphan Drugs
x
Um unsere Webseite für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies erhalten Sie in unserer Datenschutzerklärung.

Market Access of Orphan Drugs

Evidence generation, value proposition and the HTA - the latest insights with regard to Orphan Drugs
  • Evidence generation, value proposition and the HTA - the latest insights with regard to Orphan Drugs

    Aims and objectives:

    The orphan drug sector is about to change. EU orphan drug and paediatric legislation is under review and the EU HTA is fast approaching - it is time for a thorough update on regulatory and HTA issues.

    This course provides the latest on marketing authorisation and market access, as well as practical tips for evidence generation and value creation.

     

    Topics:

    - Evidence generation with small patient groups
    - Evaluation of the orphan and paediatric legislation
    - Orphan drugs in the German AMNOG procedure
    - Value proposition from a health insurance perspective
    - Value creation process for a launch in the EU4 and the UK

     

    Who should attend?

    This course addresses the needs of all who are involved in regulatory affairs or market access with small patient groups or orphan drug status. It is also recommended for those who address medical affairs and clinical issues related to orphan drugs.

    0.0 0.0
Wann 21.01.2022
von 09:00 bis 17:00
Veranstaltungsort online
Stadt online
Termin übernehmen vCal
iCal

Aims and objectives:

The orphan drug sector is about to change. EU orphan drug and paediatric legislation is under review and the EU HTA is fast approaching - it is time for a thorough update on regulatory and HTA issues.

This course provides the latest on marketing authorisation and market access, as well as practical tips for evidence generation and value creation.

 

Topics:

- Evidence generation with small patient groups
- Evaluation of the orphan and paediatric legislation
- Orphan drugs in the German AMNOG procedure
- Value proposition from a health insurance perspective
- Value creation process for a launch in the EU4 and the UK

 

Who should attend?

This course addresses the needs of all who are involved in regulatory affairs or market access with small patient groups or orphan drug status. It is also recommended for those who address medical affairs and clinical issues related to orphan drugs.

FORUM Institut für Management

Programm

2201235.pdf — PDF document, 314 kB (322,065 bytes)